TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: A prospective study
In cancer patients, plasma often contains mutant DNA released by cancer cells. We have assessed the significance of plasma DNA mutations for subsequent cancer development in healthy subjects in a large longitudinal prospective study. The European Prospective Investigation into Cancer and Nutrition s...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2006
|
| _version_ | 1797096231395131392 |
|---|---|
| author | Gormally, E Vineis, P Matullo, G Veglia, F Caboux, E Le Roux, E Peluso, M Garte, S Guarrera, S Munnia, A Airoldi, L Autrup, H Malaveille, C Dunning, A Overvad, K Tjønneland, A Lund, E Clavel-Chapelon, F Boeing, H Trichopoulou, A Palli, D Krogh, V Tumino, R Panico, S Bueno-De-Mesquita, H |
| author_facet | Gormally, E Vineis, P Matullo, G Veglia, F Caboux, E Le Roux, E Peluso, M Garte, S Guarrera, S Munnia, A Airoldi, L Autrup, H Malaveille, C Dunning, A Overvad, K Tjønneland, A Lund, E Clavel-Chapelon, F Boeing, H Trichopoulou, A Palli, D Krogh, V Tumino, R Panico, S Bueno-De-Mesquita, H |
| author_sort | Gormally, E |
| collection | OXFORD |
| description | In cancer patients, plasma often contains mutant DNA released by cancer cells. We have assessed the significance of plasma DNA mutations for subsequent cancer development in healthy subjects in a large longitudinal prospective study. The European Prospective Investigation into Cancer and Nutrition study was analyzed with a nested case-control design. Cases were nonsmokers or ex-smokers for >10 years and newly diagnosed with lung, bladder, or upper aerodigestive tract cancers or leukemia accrued after a median follow-up of 6.3 years. Controls were matched 2:1 for follow-up, age, sex, area of recruitment, and smoking status. KRAS2 mutations were detected by mutant-enriched PCR and sequencing (n = 1,098). TP53 mutations were detected by denaturing high-performance liquid chromatography, temporal temperature gradient electrophoresis, and sequencing (n = 550). KRAS2 or TP53 mutations were detected in 13 of 1,098 (1.2%) and 20 of 550 (3.6%) subjects, respectively, 16 of whom developed cancer on average after 18.3 months of follow-up. Among 137 subjects who developed bladder cancer, 5 had KRAS2 mutations [odds ratio (OR), 4.25; 95% confidence interval (95% CI), 1.27-14.15] and 7 had TP53 mutations (OR, 1.81; 95% CI, 0.66-4.97). There was a nonsignificant trend for association between TP53 mutations and bulky adducts in lymphocyte DNA (OR, 2.78; 95% CI, 0.64-12.17). This is the first report of TP53 or KRAS2 mutations in the plasma of healthy subjects in a prospective study, suggesting that KRAS2 mutation is detectable ahead of bladder cancer diagnosis. TP53 mutation may be associated with environmental exposures. These observations have implications for monitoring early steps of carcinogenesis. ©2006 American Association for Cancer Research. |
| first_indexed | 2024-03-07T04:39:03Z |
| format | Journal article |
| id | oxford-uuid:d0fbee73-8087-4d92-9658-77345799bb74 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:39:03Z |
| publishDate | 2006 |
| record_format | dspace |
| spelling | oxford-uuid:d0fbee73-8087-4d92-9658-77345799bb742022-03-27T07:53:54ZTP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: A prospective studyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d0fbee73-8087-4d92-9658-77345799bb74EnglishSymplectic Elements at Oxford2006Gormally, EVineis, PMatullo, GVeglia, FCaboux, ELe Roux, EPeluso, MGarte, SGuarrera, SMunnia, AAiroldi, LAutrup, HMalaveille, CDunning, AOvervad, KTjønneland, ALund, EClavel-Chapelon, FBoeing, HTrichopoulou, APalli, DKrogh, VTumino, RPanico, SBueno-De-Mesquita, HIn cancer patients, plasma often contains mutant DNA released by cancer cells. We have assessed the significance of plasma DNA mutations for subsequent cancer development in healthy subjects in a large longitudinal prospective study. The European Prospective Investigation into Cancer and Nutrition study was analyzed with a nested case-control design. Cases were nonsmokers or ex-smokers for >10 years and newly diagnosed with lung, bladder, or upper aerodigestive tract cancers or leukemia accrued after a median follow-up of 6.3 years. Controls were matched 2:1 for follow-up, age, sex, area of recruitment, and smoking status. KRAS2 mutations were detected by mutant-enriched PCR and sequencing (n = 1,098). TP53 mutations were detected by denaturing high-performance liquid chromatography, temporal temperature gradient electrophoresis, and sequencing (n = 550). KRAS2 or TP53 mutations were detected in 13 of 1,098 (1.2%) and 20 of 550 (3.6%) subjects, respectively, 16 of whom developed cancer on average after 18.3 months of follow-up. Among 137 subjects who developed bladder cancer, 5 had KRAS2 mutations [odds ratio (OR), 4.25; 95% confidence interval (95% CI), 1.27-14.15] and 7 had TP53 mutations (OR, 1.81; 95% CI, 0.66-4.97). There was a nonsignificant trend for association between TP53 mutations and bulky adducts in lymphocyte DNA (OR, 2.78; 95% CI, 0.64-12.17). This is the first report of TP53 or KRAS2 mutations in the plasma of healthy subjects in a prospective study, suggesting that KRAS2 mutation is detectable ahead of bladder cancer diagnosis. TP53 mutation may be associated with environmental exposures. These observations have implications for monitoring early steps of carcinogenesis. ©2006 American Association for Cancer Research. |
| spellingShingle | Gormally, E Vineis, P Matullo, G Veglia, F Caboux, E Le Roux, E Peluso, M Garte, S Guarrera, S Munnia, A Airoldi, L Autrup, H Malaveille, C Dunning, A Overvad, K Tjønneland, A Lund, E Clavel-Chapelon, F Boeing, H Trichopoulou, A Palli, D Krogh, V Tumino, R Panico, S Bueno-De-Mesquita, H TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: A prospective study |
| title | TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: A prospective study |
| title_full | TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: A prospective study |
| title_fullStr | TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: A prospective study |
| title_full_unstemmed | TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: A prospective study |
| title_short | TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: A prospective study |
| title_sort | tp53 and kras2 mutations in plasma dna of healthy subjects and subsequent cancer occurrence a prospective study |
| work_keys_str_mv | AT gormallye tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT vineisp tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT matullog tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT vegliaf tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT cabouxe tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT lerouxe tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT pelusom tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT gartes tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT guarreras tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT munniaa tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT airoldil tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT autruph tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT malaveillec tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT dunninga tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT overvadk tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT tjønnelanda tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT lunde tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT clavelchapelonf tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT boeingh tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT trichopouloua tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT pallid tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT kroghv tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT tuminor tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT panicos tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy AT buenodemesquitah tp53andkras2mutationsinplasmadnaofhealthysubjectsandsubsequentcanceroccurrenceaprospectivestudy |